AlphaTON Capital (ATON) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Management team and governance
CEO is Brittany Kaiser, who also serves as the principal executive officer and authorized U.S. representative.
Wes Levitt is the Chief Financial Officer and principal financial and accounting officer.
Board includes Enzo Villani (Executive Chairman), Steven Mintz, Alexander Pickett, and Michael Terpin as directors.
Directors and officers are indemnified to the extent permitted by British Virgin Islands law, provided actions are in good faith and not unlawful.
Director and officer insurance is maintained.
Offering details and pricing
Registration statement filed on Form F-3 for securities to be offered from time to time after effectiveness.
Securities may be offered on a delayed or continuous basis under Rule 415.
Includes forms for cash and cryptocurrency securities purchase agreements, registration rights, and pre-funded warrants.
Underwriters and syndicate
Legal counsel includes Hogan Lovells US LLP and Forbes Hare LLP.
Latest events from AlphaTON Capital
- Shifted to TON-focused digital assets, raising $36.2M but facing liquidity and going concern risks.ATON
Q2 202618 Mar 2026 - Shelf registration targets $420.7M for TON token treasury and biotech R&D, with high risk factors.ATON
Registration Filing16 Dec 2025 - Up to $40M in securities offered to support R&D, operations, and strategic options amid financial pressures.ATON
Registration Filing16 Dec 2025 - Seeking $40M shelf offering to fund R&D and operations amid financial and Nasdaq compliance pressures.ATON
Registration Filing16 Dec 2025 - Major capital shift to TON token, 7.47M shares registered for resale, high dilution risk.ATON
Registration Filing16 Dec 2025 - Up to 189,719 shares are offered for resale as the company pivots to a TON token-focused strategy.ATON
Registration Filing16 Dec 2025 - Net loss dropped sharply year-over-year as non-cash charges and operating expenses declined.ATON
Q4 202525 Jul 2025 - Net loss narrowed and costs fell as Portage Biotech explores strategic options amid trial pauses.ATON
Q2 202513 Jun 2025 - Net loss improved to $1.7M as R&D spending dropped and strategic options are being explored.ATON
Q1 202513 Jun 2025